Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
about
Muscle-invasive urothelial bladder cancer: an update on systemic therapyTargeted therapy in advanced bladder cancer: what have we learned?Role of systemic chemotherapy in urothelial urinary bladder cancerMultimodal management of muscle-invasive bladder cancerCytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Bladder Sparing Approaches for Muscle-Invasive Bladder CancersAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancerPhase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.Systemic therapy in bladder cancerSurvival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.Penile cancer: current therapy and future directions.Concomitant urothelial cancer and renal tuberculosis.Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.Systemic therapy for bladder cancer - a medical oncologist's perspective.First- and second-line therapy for metastatic urothelial carcinoma of the bladderSarcopenia as a prognostic biomarker of advanced urothelial carcinomaNovel agents for advanced bladder cancer.Current therapeutic strategies for invasive and metastatic bladder cancer.Urothelial carcinomas: a focus on human epidermal receptors signalingControversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.Chemotherapy in advanced bladder cancer: current status and futureSuccessful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyProgrammed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patientsSequential therapy with gemcitabine and Carboplatin followed by Paclitaxel as first line treatment for advanced urothelial cancer.Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples.Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.Novel strategies for treating relapsed/refractory urothelial carcinoma.Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).
P2860
Q26775780-2E23BA77-DB2D-4DCB-9268-500370797A69Q27009469-1B8515A4-B2F4-497D-ABA2-A36D3D87FDB4Q27010323-452A905E-0916-42A5-B163-A44D10F08D21Q27011624-CD8C25E5-A342-41C2-B1D5-AAAE79DA3C73Q27026717-C52E1A26-D7F6-483A-AD48-F60F843D5EDFQ28072814-BF491739-8101-472C-9D88-920F4E58E2D1Q30275266-A09CF0B7-3523-4F9F-873A-1BAD9D541540Q33411962-5056E04B-E1ED-482A-A38B-957C0E08FE0AQ33412123-62C0A5DF-1328-4B37-AF3B-D51340B343DAQ33426694-1F0991E5-C35C-410C-BC5B-0D6C97B2F8E5Q33431220-EF2677E4-4410-483D-9833-8EDE5558E90CQ33435967-5227DBA3-1FC7-4548-8B81-3A57DFF762D0Q33578564-E1785ADA-A770-4DD6-8040-EE323C22E6B6Q33614498-517693C5-9D4B-4647-A32B-85E234D03DEAQ33718095-1D5ECD0E-DC9E-4DC0-8D2D-2B807817F5CDQ34009724-9EA1B676-DC0A-42D9-BB78-3285B0103BE0Q34438928-61D6EB75-7AB6-418A-92F0-B0D840E76BF1Q34516731-3855D419-0772-467C-B878-0B4235E5753AQ34541463-B70DB73A-607A-4685-9527-B9EAE2C60ABAQ35001652-EE88B01B-B917-49F8-84F9-4479DF42A448Q35076184-68E4066F-3C8A-45EA-BC67-9F014423F45AQ35128721-A5559817-E3DB-425D-B6EE-54B98543AA9AQ35172558-EA375CB8-D28C-4B54-83D0-312A6FD36C28Q35180823-41124397-34CA-48B1-A929-A1D8241C7D1AQ35227771-4584AE5D-09CE-43B9-B1B7-9B96231D15E9Q35554515-D566F50C-B990-46A6-9DCD-DBEA3DC35861Q35677288-E4C29E2F-967C-41E0-8076-D9824CCB3D63Q35771672-44CA3279-5522-4154-9456-F7D692B4F322Q36141581-4A59BB14-9111-435D-B7F1-53A847C446DAQ36316576-F2CE049B-7DFF-40F6-AD82-8B0A5C0C51DDQ36589753-F0F8530C-D54D-403D-8F8C-D4CEBDB6AED0Q36859124-F702EA98-66D3-4FF5-AFC6-AF1997EAC832Q36953563-15555146-E6E8-43AD-8F8D-0FB0026B9147Q36953789-447E59D6-D855-46AF-99F6-51ED4BDC45DAQ36995686-29EBF99B-3D01-434C-BEC5-DBEE93B7BAC6Q37163829-74173012-459D-4079-9DEE-049795F18AF8Q37234834-CCAE0235-B7BA-40CC-B644-5F26B83A0CBEQ37459636-212EBEF5-E8E2-4023-80CD-F5E270430950Q37474079-3226F163-D057-4B46-A7B9-0B4501B265C1Q37475193-AE1A9EE0-DABD-4561-99ED-D1F3A7284A41
P2860
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Randomized phase III study com ...... EORTC Intergroup Study 30987.
@ast
Randomized phase III study com ...... EORTC Intergroup Study 30987.
@en
type
label
Randomized phase III study com ...... EORTC Intergroup Study 30987.
@ast
Randomized phase III study com ...... EORTC Intergroup Study 30987.
@en
prefLabel
Randomized phase III study com ...... EORTC Intergroup Study 30987.
@ast
Randomized phase III study com ...... EORTC Intergroup Study 30987.
@en
P2093
P2860
P356
P1476
Randomized phase III study com ...... EORTC Intergroup Study 30987.
@en
P2093
Andreas Boehle
Christine Chevreau
Derek Raghavan
Eric Winquist
Graham M Mead
Hans von der Maase
Iwona Skoneczna
Joaquim Bellmunt
Leslie R Laufman
Luis Paz-Ares
P2860
P304
P356
10.1200/JCO.2011.38.6979
P407
P577
2012-02-27T00:00:00Z